I MAB Quote - IMAB | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
USA
NASDAQ
I MAB (IMAB) Share Price

I MAB (IMAB)

1.03

-0.01

( -0.96% )

Updated: 01:47:14

Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Current Price

1.03

Bid

1.02

Offer

1.04

Volume

31,322

1.02 Day's Range 1.07

0.00 52 Week Range 0.00

Market Cap

Previous Close

1.04

Open

1.05

Last Trade

Last Trade Time

01:49:07

Financial Volume

US$ 32,829

VWAP

1.0481

Average Volume (3m)

-

Shares Outstanding

80,701,592

Dividend Yield

-

PE Ratio

0.00

Earnings Per Share (EPS)

-

Revenue

27.64M

Net Profit

-1.47B

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-actin... I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.i-mabbiopharma.com

Headquarters

Grand Cayman, Cym

Founded

-

I MAB is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMAB. The last closing price for I MAB was US$1.04. Over the last year, I MAB shares have traded in a share price range of US$ 0.00 to US$ 0.00.

I MAB currently has 80,701,592 shares in issue. The market capitalisation of I MAB is US$83.93 million.

I-Mab to Participate at the Piper Sandler Healthcare Conference

I-Mab to Participate at the Piper Sandler Healthcare Conference PR Newswire ROCKVILLE, Md., Nov. 21, 2024 The 36th Annual Healthcare Conference will be held in New York, December 3-5...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Reports Third Quarter 2024 Results

I-Mab Reports Third Quarter 2024 Results PR Newswire ROCKVILLE, Md., Nov. 14, 2024 Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer PR Newswire ROCKVILLE, Md., Nov. 6, 2024 ROCKVILLE, Md., Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

I-Mab to Release Q3 2024 Financial Results on November 14, 2024 PR Newswire ROCKVILLE, Md., Oct. 31, 2024 ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a...

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024 PR Newswire ROCKVILLE, Md., Oct. 30, 2024 - Poster to be presented in a late-breaking abstract session at the...

I-Mab to Participate at the Truist Securities BioPharma Symposium

I-Mab to Participate at the Truist Securities BioPharma Symposium PR Newswire ROCKVILLE, Md., Oct. 28, 2024 ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PALIPalisade Bio Inc	US$ 3.05 (117.86%)	40.21M
TRVITrevi Therapeutics Inc	US$ 4.2076 (68.98%)	26.8M
LAESSEALSQ Corporation	US$ 1.9209 (67.03%)	95.62M
TRUGTruGolf Holdings Inc	US$ 0.5918 (34.20%)	3.66M
AMPGAmplitech Group Inc	US$ 2.555 (32.38%)	22.25M
SPGCSacks Parente Golf Inc	US$ 0.3014 (-78.47%)	8.5M
KROSKeros Therapeutics Inc	US$ 16.885 (-75.40%)	3.31M
TFFPTFF Pharmaceuticals Inc	US$ 0.0695 (-57.28%)	2.3M
SFHGSamfine Creation Holdings Group Ltd	US$ 1.35 (-55.74%)	2.01M
AVGRAvinger Inc	US$ 0.440099 (-46.33%)	281.78k
LAESSEALSQ Corporation	US$ 1.92 (66.96%)	95.7M
CDTConduit Pharmaceuticals Inc	US$ 0.0928 (5.10%)	72.26M
PALIPalisade Bio Inc	US$ 3.041 (117.21%)	40.25M
RGTIRigetti Computing Inc	US$ 7.13 (-3.39%)	26.89M
TRVITrevi Therapeutics Inc	US$ 4.2012 (68.72%)	26.83M

glenn1919

glenn1919 2 months ago

IMAB.......................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 2 months ago

IMAB.................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 3 months ago

Monksdream

Monksdream 5 months ago

Monksdream

Monksdream 5 months ago

stock1ace1

stock1ace1 7 months ago

Imab $1.80 golden cross https://schrts.co/CNBigxhc

I-Mab Price Target Maintained With a $6.00/Share by Needham
Mentioned: IMAB

Ratings actions from Benzinga: https://www.benzinga.com/quote/IMAB/analyst-ratings

(END) Dow Jones Newswires

April 12, 2024 06:15 ET (10:15 GMT)

Monksdream

Monksdream 8 months ago

IMAB 10Q due 4/3

Monksdream

Monksdream 9 months ago

Monksdream

Monksdream 9 months ago

Monksdream

Monksdream 10 months ago

AGORDON

AGORDON 10 months ago

IMAB
This is a long-term deal. The China divestiture had to be done to facilitate the future sale of the company. There would be too many Chinese entities to satisfy and hence introduce uncertainty in a future sale. The loss of the Jumpcan deal is a negative because the numbers were spelled out. I will feel much more comfortable about IMAB after they get a Giva or a Uli licensing deal. Combined, based on prior deals for similar drugs would be worth $1B+. It is likely they will have to pay out $30M to the non participants. The $80M from Hangzhou will take years to collect. But, there is one point that has not been addressed. That is the pricing of drugs in China. The Chinese government is notorious for asking for discounts. The pricing of drugs in the USA is better. IMAB has shifted its focus to drugs in a market where they will get much better pricing. The unknown is will IMAB get a deal for Giva, or Uli ?

AGORDON

AGORDON 12 months ago

2-3 minutes before the close over 500k shares were dumped. Same exercise happened to several Chinese stocks.

AGORDON

AGORDON 12 months ago

Based on the Astra Zeneca agreement with KYM for their Claudin 18.2 drug, and the Antengene agreement with Calithera for their CD73 inhibitor drug, I estimate that IMAB has potential contracts worth $1.25B+.

AGORDON

AGORDON 12 months ago

Why doesn't IMAB license Givasgtomig and Ulilidimab? I estimate that the milestone payments would be at least $500M. The share would be at least $5.

AGORDON

AGORDON 1 year ago

From the 20-F report

On July 16, 2022, I-Mab Hangzhou entered into a definitive financing agreement with a group of domestic investors in China to raise approximately US$46 million (in RMB equivalent). On the same date, we, through our wholly-owned subsidiary, entered into a shareholders agreement with I-Mab Hangzhou and other domestic investors in I-Mab Hangzhou named therein (the “I-Mab Hangzhou Shareholders Agreement”). Upon the occurrence of certain triggering events as specified in the I-Mab Hangzhou Shareholders Agreement, including but not limited to I-Mab Hangzhou’s failure to accomplish certain public offering condition, we may be obligated to repurchase the equity held by other domestic investors in cash or in our stocks in the period beyond 12 months.

AGORDON

AGORDON 1 year ago

In the most recent reporting period, Decheng Capital purchased 4 million shares of IMAB.

AGORDON

AGORDON 1 year ago

The stock has bounced off $1.80 two times within a month.

AGORDON

AGORDON 1 year ago

Not a surprise to see a pull back from the +50% rise last week. A large order came in at the end of yesterday. Nevertheless, it is disappointing to see the slide. It could fall back to $1.28. Mr. Kannan will be at a conference on 11/14. I think the China approvals will send the stock past $3 next year. The company will be sold by the end of 2025.

Mt. Blanc

Mt. Blanc 1 year ago

IMAB climbing the charts tracking the $3s. Check it out soon.

mb

Monksdream

Monksdream 1 year ago

Olympia Financial (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions